Rationale for Correct Answer
The correct answer is: In phase 3 placebo-controlled trials, upadacitinib was an effective treatment for both CD and UC
In phase 3 placebo-controlled trials, the JAK-inhibitor upadacitinib was an effective treatment for both CD and UC.1,2 Filgotinib has demonstrated efficacy for management of UC3, although it is not an FDA-approved treatment. Upadacitinib and filgotinib are both selective for JAK1 receptors.1,3
References:
1. Loftus EV Jr et al. N Engl J Med. 2023;388(21):1966-80;
2. Danese S et al. Lancet. 2022;399(10341):2113-28;
3. Feagan B et al. Lancet. 2021;397(10292):2372-84.